RT Journal Article
SR Electronic
T1 A combined risk model shows viability for personalized breast cancer risk assessment in the Indonesian population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.22.23295602
DO 10.1101/2023.09.22.23295602
A1 Rabbani, Bijak
A1 Tanu, Sabrina Gabriel
A1 Ramanto, Kevin Nathanael
A1 Audrienna, Jessica
A1 Aldila, Fatma
A1 Fernandez, Eric Aria
A1 Gonzalez-Porta, Mar
A1 Valeska, Margareta Deidre
A1 Haruman, Jessline
A1 Ulag, Lorina Handayani
A1 Maulana, Yusuf
A1 Junusmin, Kathleen Irena
A1 Amelia, Margareta
A1 Gabriella, Gabriella
A1 Soetyono, Feilicia
A1 Fajarrahman, Aulian
A1 Hasan, Salma Syahfani Maudina
A1 Agatha, Faustina Audrey
A1 Wijaya, Marco
A1 Sormin, Stevany Tiurma Br
A1 Sani, Levana
A1 Ali, Soegianto
A1 Irwanto, Astrid
A1 Haryono, Samuel J
YR 2023
UL http://medrxiv.org/content/early/2023/10/20/2023.09.22.23295602.abstract
AB Breast cancer remains a significant concern worldwide, with a rising incidence in Indonesia. This study aims to evaluate the applicability of risk-based screening approaches in the Indonesian demographic through a case-control study involving 305 women. We developed a personalized breast cancer risk assessment workflow that integrates multiple risk factors, including clinical (Gail) and polygenic (Mavaddat) risk predictions, into a consolidated risk category. By evaluating the area under the receiver operating characteristic curve (AUC) of each single-factor risk model, we demonstrate that they retain their predictive accuracy in the Indonesian context (AUC for clinical risk: 0.67 [0.61,0.74]; AUC for genetic risk: 0.67 [0.61,0.73]). Notably, our combined risk approach enhanced the AUC to 0.70 [0.64,0.76], highlighting the advantages of a multifaceted model. Our findings demonstrate for the first time the applicability of the Mavaddat and Gail models to Indonesian populations, and show that within this demographic, combined risk models provide a superior predictive framework compared to single-factor approaches.Competing Interest StatementThe authors are affiliated with their respective organizations. BR, SGT, KNR, JA, FA, EAF, MGP, MDV, JH, LHU, YM, KIJ, MA, GG, FS, AF, SSM, LS and AI are affiliated with NalaGenetics. NalaGenetics is a biotech company focusing on personalized medications, diet, and screening. The risk prediction tool investigated in the study was developed by NalaGenetics. FAA, MW, STBS, AW, AS and SJH are affiliated with SJH Initiatives. SJH Initiatives is a research body under MRCCC Siloam Hospitals network whose one of the main focuses is on breast cancer research. SA is affiliated with Atma Jaya Catholic University of Indonesia. Atma Jaya is a private Catholic university based in Jakarta, Indonesia. The authors have no financial gain or loss in any form that could result from the publication of this manuscript, but the absence of authors without any organizational affiliation could be considered a non-financial competing interest.Funding StatementThis study was funded by Nalagenetics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical & Health Research Ethics Commission of MRCCC Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.